The Appropriate Elicitation of Expert Opinion in Economic Models

Decision-analytic modelling has become an indispensible method to inform healthcare resource allocation decision making. Prospective randomized economic trials can produce internally robust cost and outcome data. However, such prospective data are typically unavailable or insufficient for the purpose of guiding national-level resource allocation decisions because results are not generalizable outside the trial study population or design. Using an economic model allows a decision analyst to carefully structure the research question and assimilate all available data. Additionally, outcome data from trials with short timeframes can be extrapolated to long-term estimates. Modelling also has a key role in prioritizing and planning future trials and research. Ideally, a model should be structured to represent all clinical pathways relevant to the decision problem. Methods guidelines state that data availability should not be a reason for rejecting a model or even an overriding factor when defining model structure. However, more often than not, the model cannot be populated using published, robust trial or observational data. Alternative data sources are then needed. Expert opinion is a recognised potential source of data and is often used to fill in data gaps and/or supplement the trial and observational data. Data elicited from experts is appropriately viewed as being second best and a potential source of parameter uncertainty. This is in part due to experts’ limited experience and perspective but also, importantly, because the methods used to identify the experts and elicit their opinion is often neither conducted robustly nor reported explicitly. Guidelines for the selection, design and population of economic models are necessary to encourage the transparent and explicit reporting of methods. Previous commentators have already noted that the methods used to elicit expert opinion for health technology assessments should also be reported explicitly. Existing methods guidelines do allude to the need for explicit reporting of expert opinion elicitation methods but do not go into methodological detail about the different elicitation methods available and their application. This commentary describes the potential use of the Delphi method as an elicitation technique. It clarifies that there are different types of Delphi that can be used, with quite distinct research and policy applications and also outlines where other expert elicitation methods might be more appropriate when focussing on the primary data requirements for economic modelling.

[1]  Mark Sculpher,et al.  Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[2]  Ron L Akehurst Making decisions on technology availability in the British National Health Service--why we need reliable models. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  S. Golder,et al.  Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.

[4]  Wolf D. Rauch,et al.  The decision Delphi , 1979 .

[5]  Karl Claxton,et al.  Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Sarah Wordsworth,et al.  Eliciting expert opinion for economic models: an applied example. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[8]  Jonathan Karnon,et al.  A Critique and Impact Analysis of Decision Modeling Assumptions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  J Chilcott,et al.  The role of modelling in prioritising and planning clinical trials. , 2003, Health technology assessment.

[10]  Andrew Briggs,et al.  Value based pricing for NHS drugs: an opportunity not to be missed? , 2008, BMJ : British Medical Journal.

[11]  Karl Claxton,et al.  The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  Per Lindqvist,et al.  (Mis-?) using the E-Delphi method. An Attempt to Articulate Practical Knowledge of Teaching , 2007 .

[13]  Kathy K. Franklin,et al.  Idea Generation and Exploration: Benefits and Limitations of the Policy Delphi Research Method , 2006 .

[14]  M. Drummond,et al.  The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment , 1997, Journal of health services research & policy.

[15]  Jeremy E. Oakley,et al.  Uncertain Judgements: Eliciting Experts' Probabilities , 2006 .

[16]  Katherine Payne,et al.  Fish and chips all round? Regulation of DNA-based genetic diagnostics. , 2009, Health economics.

[17]  Laura Vallejo-Torres,et al.  Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach , 2008, International Journal of Technology Assessment in Health Care.

[18]  C M Goodman,et al.  The Delphi technique: a critique. , 1987, Journal of advanced nursing.

[19]  C. Evans,et al.  Expert judgement in pharmacoeconomic studies. Guidance and future use. , 2000, PharmacoEconomics.

[20]  W. Newman,et al.  Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom , 2010, British Journal of Cancer.

[21]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.